Abstract: A separation device including a first buoy, a second buoy, a first valve, and a second valve. The first buoy is mounted to a buoy guide post and slidably mounted within a separation chamber. The second buoy is slidably mounted to the guide post and movable between a first position and a second position. The second buoy closes the first valve and opens the second valve when in the first position. The second buoy opens the first valve and closes the second valve when in the second position. The second buoy has a density such that after spinning the device for a suitable period of time a first component of the composition is isolated between the first buoy and the second buoy and a second component of the composition is isolated between the second buoy and the end of the separation chamber that is opposite to a port.

Abstract: The present invention relates to a method of adapting of a second threshold window of at least a second measured variable depending on the change of a first threshold window of a first measured variable, wherein the adaptation is performed by the use of a control unit having been provided and/or configured therefor. The present invention further relates to a control device, a medical treatment apparatus, a medical monitoring apparatus, a digital storage means, a computer program product and a computer program.

Abstract: Methods and apparatus are disclosed co-culturing stem cells with mononuclear cells and/or lymphocytes to modulate their function. The invention also discloses the use of stem cells to educate autoreactive immune cells as a mechanism to treat autoimmune diseases and immune disorder-related diseases, such as diabetes. In one aspect of the invention, bioreactors are disclosed closed for modulating lymphocytes and suppressing autoreactive T cells. The bioreactors can include a chamber having at least one positively charged and/or hydrophobic substrate surface, a population of stem cells attached to the substrate surface, an inlet conduit for introducing lymphocytes into the chamber, and an outlet conduit for extracting treated lymphocytes following co-culturing with the stem cells.

Abstract: A method for separating a volume of whole blood contained in a separation bag into at least three components comprising centrifuging the separation bag so as to separate therein a first inner layer comprising plasma, a second intermediate layer comprising platelets, a third intermediate layer comprising lymphocytes, monocytes and granulocytes and a fourth outer layer comprising red blood cells, transferring, into a plasma component bag connected to the separation bag, a plasma component and transferring into a mononuclear cell component bag a mononuclear cell components.

Abstract: A pump cassette is disclosed. The pump cassette includes a housing having at least, one fluid inlet line and at least one fluid outlet line. The cassette also includes at least one reciprocating pressure displacement membrane pump within the housing. The pressure pump pumps a fluid from the fluid inlet line to the fluid outlet line. A hollow spike is also included on the housing as well as at least one metering pump. The metering pump is fluidly connected to the hollow spike on the housing and to a metering pump fluid line. The metering pump fluid line is fluidly connected to the fluid outlet line.

Abstract: A wound closure apparatus is provided which utilizes blood fluid by activating the clotting cascade of blood fluid outside the body within a substantially enclosed sterile container then introducing, the blood fluid to the wound site to complete clotting. An apparatus for providing ways of inhibiting anticoagulating agents, and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with, and/or associated with preferred procedures are also disclosed. The invention provides a clotting cascade initiation apparatus (1) including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources can be received, and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

Abstract: This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby certain growth factor receptors (sFlt-1) circulating in the blood of a pregnant woman at risk of developing pre-eclampsia are selectively removed by passing the blood through a cartridge containing immobilized anti-sFlt-1 aptamers. The circulating sFlt-1 is bound out by the immobilized anti-sFlt-1 aptamers and the cleaned blood is returned to the patient. Removal of circulating sFlt-1 will diminish the risk of developing eclampsia during pregnancy.

Abstract: The invention relates to a calculation and control system for determining whether a patient intended to follow several sessions of hemodialysis treatment falls or not within one group among several groups of hypertension-affected patients, the system comprising: a) means for determining the value of at least one parameter representing the mass interdialytic evolution of the patient, for at least two sessions, b) means for determining the value of at least one parameter representing the plasmatic conductivity of the patient for at least two sessions, c) means for determining the value of a parameter representing the ionic mass transfer of the treatment for at least two sessions, d) programmed means for determining whether the patient falls or not within a group of hypertension-affected patients as a function of the interdialytic mass evolution of the patient, and/or of the plasmatic conductivity and/or of the ionic mass transfer.

Abstract: The present disclosure provides apparatus and methods for removing thrombus outside of a hemodialysis. The hemodialysis catheter comprises an elongate shaft comprising a plurality of lumens. A first lumen has a first distal port. The first lumen is configured for the flow of a fluid in a first direction. A second lumen has a second distal port proximal to the first distal port. The second lumen is configured for the flow of the fluid in a second direction opposite to the first direction. A third lumen has a third distal port proximal to the second distal port. An elongate device is disposed through the third lumen. The elongate device has an operable member on a distal end or a device to connect to an operable member disposed on the elongate shaft. The operable member is configured to engage and remove thrombus from an exterior surface on the elongate shaft.

Abstract: A biologic ventricular assist device that also has the capability to capture, grow, and administer stem cells to regenerate and restore damaged myocardium in the heart. The device works in conjunction with a traditional ventricular assist device and possesses an additional external path or tube that is in-line with the path of the ventricular assist device. The external path allows for the administration of stem cells, genes, genetically modified cells or other therapeutic biologic or pharmacologic agents, as well as leading to a stem cell collecting accessory (14) that captures circulating stem cells. The stem cell collecting accessory is also associated with a chamber (39) for culturing the captured stem cells.

Abstract: A process for detoxifying the blood of a patient in need thereof involves: collecting albumin from human plasma and/or plasma fractions; diafiltration of a mixture containing the collected albumin; stabilizing the resulting diafiltered albumin mixture with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin mixture; diafiltering the pasteurized mixture to remove, among other things, stabilizers; and detoxifying the blood of the patient by administering the resulting albumin to the patient. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.

Abstract: A blood processing system is disclosed which is adapted for single or double access draw and return. The blood processing system includes a blood processor for separating blood (or blood components) into one or more components or other components. In one embodiment the blood processor includes an inlet for receiving blood from blood source and an outlet for returning at least one blood component to the source. The processing system includes a first flow path in communication with the inlet, a second flow path in communication with the outlet, a third flow path in communication with a second flow path at two spaced apart locations, a reservoir communicates with the third flow path between the two spaced apart locations, and a flow communication site associated with the second flow path downstream of the spaced apart locations which communication site is adapted to permit communication with the first flow path.

Abstract: Provision of a blood purification system comprising a blood purification tubing and a blood purification apparatus particularly suitable for use in continuous hemofiltration in which in the treatment of a patient with renal disease, multiple organ failure, and the like, the amount of water removed from the patient and the amount of supply to the patient can be more accurately controlled, and in which preparation operation is easy. A blood purification system comprising a blood purification tubing and a blood purification apparatus wherein the soft tubes of flow paths connecting a first planar panel and a second planar panel, and the location of the soft tubes are selected to satisfy a formula of a predetermined condition.

Abstract: Method and apparatus for separating plasma from blood in a membrane separator and further separator the separated plasma into desired plasma proteins in a plasma separator fluidly connected to the membrane separator to receive the separated plasma.

Abstract: A method for batch implementation of settings in a renal replacement therapy device including: displaying on a user interface control settings which may be manually selected by an operator; selecting an independent control setting of the plurality of control settings; adjusting the independent control setting to an independent control setting level selected by an operator; temporarily storing the adjusted independent control setting level; automatically adjusting a dependent control setting level based upon the independent control level; displaying the adjusted independent control setting level and the adjusted dependent control setting, and implementing both the adjusted independent control setting level and the adjusted dependent control setting to control the device, by actuating a batch setting acceptance operation.

Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.

Abstract: Systems and methods for controlling hematocrit during a blood processing procedure. In one aspect, a system includes a first flow path for flowing whole blood from a patient. A separator communicates with the first flow path for separating at least red blood cells from plasma. Second and third flow paths communicate with the separator for respectively flowing the separated plasma and red blood cells from the separator. A flow controller is associated with the second and third flow paths to control fluid communication between the second and third flow paths and addition of separated plasma to the separated red blood cells. The resulting red blood cells and plasma has a resulting hematocrit. Hematocrit is calculated or sensed in operative association with the third flow path and communicated to the flow controller for controlling the amount of plasma added to the third flow path and the resulting hematocrit.

Abstract: A device that allows for serial (time) use of clean blood filters during the use of a heart lung machine. The device is comprised of a series of filters and a switching mechanism that allows the new filter to be placed in the blood flow pathway while at the same time removing the old (previous) filter. A clean filter is always available, and filters for specific components of blood or those able to bind and remove specific biochemicals can be used.

Abstract: A medical fluid management apparatus which includes a plurality of processor systems with respectively associated software programs. The fluid management apparatus has a fluid treatment component and/or a fluid source which can be connected to a patient via a fluid line. The processor systems are connected via a data transfer system to a data input apparatus via which an updating of the software programs belonging to the respective processor systems can take place. After actuation of an operating mode switch, a detection system, while taking into account the existing version of the software programs and/or the existing processor systems, determines which software programs have to be loaded via the data input apparatus. The medical fluid management apparatus allows a simple and user-friendly updating of the operating software even with a complex design of the apparatus.

Abstract: A device for separating and isolating components of a biological fluid comprising a container for containing the fluid to be processed, a tube cap assembly for closing the container while providing filling and extraction communication therewith, a float assembly disposed within the container for funneling and controlling biological fluid flow into an inverted domed shaped isolation chamber within the float and controlling the biological fluid flow out of the isolation chamber for effecting an encapsulation or a sealed isolation of at least one component or fraction of the biological fluid flow within the isolation chamber during a centrifugation process. The device further comprising a flexible tube for connecting an extraction passageway disposed within the float assembly and an extraction valve of the tube cap assembly for allowing extraction of at least the one component or fraction encapsulated or isolated within the chamber.

Abstract: The invention relates to a device and to a method for monitoring access to vessels during extracorporeal blood treatment. The invention forms a loop in the arterial and/or venous line and provides device for fixing a section of the line in a loop. When the line is stressed under tension, the loop contracts and the line finally kinks. The modification of the diameter of the line and the formation of a kink in the line leads to a rise of pressure in the line, which is monitored by a pressure monitoring device. If the pressure exceeds a predetermined threshold value, the aspirating cannula is in danger of slipping out of the vessel access or has partially or completely slipped out, thus allowing the threshold value to be determined for alarms.

Abstract: An apparatus is disclosed that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Abstract: This invention describes a method for pumping or delivering fluids utilizing a flexible vessel subject to controlled pressures within another pressure vessel. The pressure vessel can be sourced with positive and/or negative (e.g., vacuum) pressure.

Abstract: A system and method for automatically adjusting a Continuous Cycling Peritoneal Dialysis (“CCPD”) therapy to minimize the potential for excess intra-peritoneal volume. The adjustments are made at the end of the drain, just prior to the next fill. The adjustments short the next fill, if necessary, to limit the intra-peritoneal volume, add a cycle, if necessary, to use all of the available dialysis solution and will average the remaining dwell time to maximize the therapeutic benefit of the therapy in the allotted time. In another embodiment, a tidal therapy using trended patient UF data is provided.

Abstract: Method and apparatus for separating plasma from blood in a separation vessel and further separator the separated plasma into desired plasma proteins in a plasma separator fluidly connected to the separation vessel to receive the separated plasma.

Abstract: Provided herein are methods and systems to increase selective thermomechanical damage to a biological body, such as a cancer cell or cell associated with a pathophysiological condition. The biological body or cancer cell is specifically targeted with nanoparticulates comprising one or more targeting moieties which form nanoparticulate clusters thereon or therewithin. Pulsed electromagnetic radiation, e.g., optical radiation, having a wavelength spectrum selected for a peak wavelength near to or matching a peak absorption wavelength of the nanoparticulates selectively heats the nanoparticulates thereby generating vapor microbubbles around the clusters causing damage to the targets without affecting any surrounding medium or normal cells or tissues. Also provided are methods for treating leukemia and for selectively and thermomechanically causing damage to cells associated with a pathophysiological condition using the methods and system described herein.

Abstract: A connection of a patient's vascular system to an extracorporeal blood treatment machine is monitored to ensure the patient's safety during a procedure. The procedure may be hemodialysis, apheresis, plasmapheresis, a coronary by-pass operation, or other procedure. To ensure safe electrical connection, a contact and a return are connected via a conductive connection into the extracorporeal blood circuit. A current is then generated between the contact and the return and is monitored by a non-contact sensor near an access site of the patient. If the current or other quantity related to the current changes significantly, a signal is sent to the machine or a controller to notify a caregiver or a medical professional. The signal may also be sent to immediately stop a blood pump or other component of the machine.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: This invention provides a method for controlling a fluid separation system, preferably a blood apheresis system having a leukocyte reduction chamber. The method utilizes at least a two-level alarm system. A first-level alarm condition is triggered in response to a pressure drop in the system to less than or equal to a specified system pressure and pauses fluid flow in at least a portion of the system. A second-level alarm condition is triggered in response to a specified number of said pressure drops within a specified period and reduces the flow rate of the fluid in the system. The alarm conditions may also trigger a visible and/or audible alarm. These alarm levels permit flow through the leukocyte reduction chamber to continue when the pressure drop is caused by a non-serious, self-resolving or easily-correctable condition such as misalignment of system components.

Abstract: The present invention is directed to devices, systems and methods for removing undesirable materials from a sample fluid by contact with a second fluid. The sample fluid flows as a thin layer adjacent to, or between, concurrently flowing layers of the second fluid, without an intervening membrane. In various embodiments, a secondary separator is used to restrict the removal of desirable substances and effect the removal of undesirable substances from blood. The invention is useful in a variety of situations where a sample fluid is to be purified via a diffusion mechanism against an extractor fluid. Moreover, the invention may be used for the removal of components from a sample fluid that vary in size. When blood is the sample fluid, for example, this may include the removal of ‘small’ molecules, ‘middle’ molecules, macromolecules, macromolecular aggregates, and cells, from the blood sample to the extractor fluid.

Abstract: Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.

Abstract: An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Abstract: A method and a device to increase the efficiency of dialysis for the removal from blood of substances that are more or less tightly bound to carriers such as albumin. According to the invention this is accomplished by a simultaneous significant increase of the flow rate of the dialysis fluid and of the area of the membrane that separates the blood from the dialysis fluid, compared to conventional dialysis.

Abstract: A method for maintaining clear passageways in an extracorporeal blood flow system. The method comprises intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. Also disclosed is an extracorporeal blood flow system. The system comprises a passageway, and a device operatively connected to provide one or more anti-clotting agents to a least a portion of said passageway.

Abstract: A method for washing multiple units of blood product including providing a centrifuge having a wash cell for each unit of blood product, balancing the centrifuge to accommodate for differences in the wash cells, and transferring supernatant including any wash solution from each unit of blood product on the centrifuge.

Abstract: A haemodialysis device having an emergency activating function is provided. In order to avoid critical drops in blood pressure during a dialysis treatment, the emergency activating function makes it possible for the operating staff to initiate with a single control function a blood pressure measurement and a delivery of substance into the patient's blood in the event of a hypotensive episode and at the same time to have the introduction of these measures by the haemodialyser confirmed clearly through a display having an outward appearance different from that displayed during normal operations. In addition, further automatically introduced process steps can be provided. The emergency activating function speeds up the implementation of the measures to be introduced and, at the same time prevents incorrect operation and makes it possible for the operating staff to attend directly to the patient.

Abstract: Systems, methods, apparatus, and computer readable media are provided for disposable component authentication with respect to a biological fluid processing device instrument. An example instrument authentication system includes a computer facilitating configuration and operation of the biological fluid processing instrument using a disposable component. A first interface is provided by the computer and is used by a service technician to configure the biological fluid processing instrument for a number of disposable components and to provide a service technician with a validation code. A key generator is to accept the validation code from the service technician and generate an authentication key in response to the entered validation code. A second interface is provided by the computer, the second interface prompting the service technician to enter an authentication key, wherein the authentication key authorizes use of a certain number of disposable components for the biological fluid processing instrument.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Abstract: The invention relates to a method for preventing or treating Alzheimer's disease (AE). According to said method, a means for inducing a sequestration of amyloid ? (A?) into a plasma is administered to a person, and the person is treated by means of an apheresis device comprising a fixed carrier that can come into contact with the blood or plasma flow and comprises a receptor binding an amyloid-?-precurser-protein (APP), the APP being removed from the blood of the person by means of the apheresis device. The invention also relates to a set for carrying out said method.

Abstract: The present invention provides a bilirubin reducing means which can minimize a risk such as the onset of an infection or the occurrence of blood coagulation and can reduce physical, temporal and economical burdens imposed on a patient suffering from liver dysfunction.

Abstract: A filtration system for collecting bone fragments during surgery performed on a patient includes a cylinder having a rotating disk with circumferential arms extending radially in the cylinder to define pockets. The rotating disk includes a longitudinal hub that carries an outlet connected to a central passageway formed in the disk. A plurality of apertures on the disk permit the liquid to flow into the passageway and through the outlet while the pockets retain the bone fragments. The disk is rotated to align circumferential spaced pockets to align with the inlet and outlet ports. The disks includes bearing surfaces that permit the rotation thereof and the arms are spaced from the cylinder inner surface to allow the flow of fluid in the event the pockets fill and clog the apertures and prevent flow into the outlet passage.

Abstract: An extracorporeal circuit, which makes it possible to efficiently collect priming solution by displacing the priming solution with blood after the priming solution is fed to the extracorporeal circuit to prime the extracorporeal circuit, includes a circuit body including first and second tubes, a feed bag that feeds the priming solution, a blood reservoir in which a liquid is temporarily stored, a third tube that branches out from the middle of the first tube, and a collection bag which communicates with the third tube and into which the priming solution is collected through the third tube. After the priming solution is fed from the feed bag to prime at least a housing, when the priming solution in the housing is displaced by blood, the priming solution in the housing is transferred and collected in the collection bag due to a height difference between the liquid level and the collection bag.

Abstract: An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Abstract: A membraneless separation device can be applied to a variety of treatments, such as the ultrafiltration of blood for a patient with end stage renal disease. An ultrafiltration device can include a membraneless separation device, which separates an incoming blood flow into a substantially cytoplasmic body-free plasma flow and remaining fraction, and a dialysate-free second stage, which selectively removes excess fluid, toxins and other substances from the plasma flow and returns the processed plasma to the membraneless separation device. A treatment protocol can include ultrafiltering blood of a patient using the ultrafiltration device and performing a secondary treatment on the blood of the patient at a reduced frequency compared to the ultrafiltering. The membraneless separation device can also be applied to treatment, analysis, and/or exchange of plasma from blood, or combined with conventional dialyzers to perform dialysis on a cytoplasmic body-free plasma fraction.

Abstract: The invention relates to a method for treating Alzheimer's disease by inducing sequestration of amyloid ? into a plasma with a A?-mimotope peptide, and treatment with an apheresis device such that a fixed carrier can come into contact with the blood or plasma flow and includes a receptor that binds to an amyloid-? precursor-protein (APP), the APP being removed from the blood with the apheresis device.